Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
While this approach can support sustainable weight management with fewer side effects, it remains off-label and lacks robust clinical data
Best for fat reduction
Survodutide (BI 456906), developed by Boehringer Ingelheim and Zealand Pharma, has completed Phase 2 trials for obesity (18.7% weight loss at 46 weeks) and MASH (62% MASH resolution), earning FDA Breakthrough Therapy Designation for MASH
If necessary, the course of treatment can be repeated throughout the year
Lingvay I, Catarig AM, Frias JP, et al
Final word: Ignore the GLP-1 meds scaremongering and focus on the facts At the end of the day, this entire media firestorm is based on a handful of cases in people who were already at risk
US$ 24.30
US$ 20.57
US$ 27.38
US$ 27.64
US$ 27.76
